William Fantegrossi
Concepts (320)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
N-Methyl-3,4-methylenedioxyamphetamine | 18 | 2023 | 34 | 5.680 |
Why?
| Cannabinoids | 15 | 2022 | 108 | 4.420 |
Why?
| Central Nervous System Stimulants | 14 | 2023 | 255 | 4.330 |
Why?
| Hallucinogens | 17 | 2023 | 62 | 4.310 |
Why?
| Benzodioxoles | 9 | 2020 | 56 | 4.300 |
Why?
| Pyrrolidines | 10 | 2020 | 88 | 4.250 |
Why?
| Receptor, Cannabinoid, CB1 | 15 | 2022 | 128 | 3.660 |
Why?
| Motor Activity | 13 | 2021 | 249 | 3.530 |
Why?
| Conditioning, Operant | 12 | 2023 | 107 | 3.520 |
Why?
| Locomotion | 8 | 2023 | 83 | 3.370 |
Why?
| Indoles | 17 | 2022 | 289 | 3.180 |
Why?
| Naphthalenes | 13 | 2022 | 126 | 3.050 |
Why?
| Behavior, Animal | 16 | 2016 | 202 | 2.980 |
Why?
| Animals | 67 | 2023 | 14409 | 2.270 |
Why?
| Cannabinoid Receptor Agonists | 9 | 2022 | 50 | 2.170 |
Why?
| Substance-Related Disorders | 10 | 2023 | 671 | 2.050 |
Why?
| Dose-Response Relationship, Drug | 25 | 2023 | 1476 | 2.040 |
Why?
| Mice | 41 | 2023 | 6428 | 1.970 |
Why?
| Body Temperature Regulation | 4 | 2020 | 35 | 1.960 |
Why?
| Discrimination Learning | 6 | 2020 | 49 | 1.900 |
Why?
| Designer Drugs | 6 | 2016 | 28 | 1.820 |
Why?
| Alkaloids | 5 | 2023 | 37 | 1.790 |
Why?
| Indazoles | 7 | 2022 | 55 | 1.640 |
Why?
| Temperature | 3 | 2023 | 177 | 1.630 |
Why?
| Cocaine | 7 | 2020 | 184 | 1.600 |
Why?
| Amphetamines | 4 | 2023 | 28 | 1.550 |
Why?
| Impulsive Behavior | 2 | 2020 | 82 | 1.380 |
Why?
| Receptor, Cannabinoid, CB2 | 5 | 2018 | 60 | 1.360 |
Why?
| Drug Tolerance | 3 | 2019 | 60 | 1.330 |
Why?
| Receptor, Serotonin, 5-HT2A | 5 | 2014 | 13 | 1.330 |
Why?
| Male | 44 | 2023 | 27347 | 1.240 |
Why?
| Dopamine | 7 | 2019 | 190 | 1.190 |
Why?
| Methamphetamine | 8 | 2020 | 233 | 1.120 |
Why?
| Telemetry | 4 | 2020 | 36 | 1.090 |
Why?
| Rats | 16 | 2023 | 3419 | 1.090 |
Why?
| Valine | 3 | 2022 | 54 | 1.070 |
Why?
| Serotonin | 4 | 2018 | 159 | 1.060 |
Why?
| Dopamine Uptake Inhibitors | 4 | 2020 | 61 | 1.050 |
Why?
| Naltrexone | 4 | 2021 | 62 | 1.030 |
Why?
| Head Movements | 2 | 2014 | 6 | 1.020 |
Why?
| Phenethylamines | 4 | 2014 | 10 | 0.990 |
Why?
| Self Administration | 11 | 2020 | 99 | 0.950 |
Why?
| Hypothermia | 2 | 2022 | 41 | 0.940 |
Why?
| Serotonin 5-HT2 Receptor Agonists | 4 | 2021 | 8 | 0.940 |
Why?
| Avoidance Learning | 2 | 2014 | 18 | 0.910 |
Why?
| Tryptamines | 3 | 2014 | 9 | 0.900 |
Why?
| Convulsants | 2 | 2022 | 7 | 0.900 |
Why?
| Receptors, Opioid, mu | 4 | 2018 | 47 | 0.840 |
Why?
| Piperidines | 11 | 2014 | 103 | 0.830 |
Why?
| Cannabinoid Receptor Antagonists | 3 | 2020 | 18 | 0.830 |
Why?
| Quinuclidines | 2 | 2019 | 42 | 0.820 |
Why?
| Serotonin Agents | 5 | 2020 | 17 | 0.810 |
Why?
| Choice Behavior | 2 | 2019 | 95 | 0.800 |
Why?
| Laboratories | 1 | 2021 | 21 | 0.800 |
Why?
| Seizures | 3 | 2022 | 209 | 0.790 |
Why?
| Neurotransmitter Uptake Inhibitors | 2 | 2018 | 7 | 0.780 |
Why?
| Rats, Sprague-Dawley | 8 | 2020 | 1664 | 0.770 |
Why?
| Body Temperature | 7 | 2017 | 83 | 0.770 |
Why?
| Biogenic Monoamines | 3 | 2017 | 12 | 0.760 |
Why?
| Alcoholism | 2 | 2021 | 249 | 0.740 |
Why?
| Stereotyped Behavior | 1 | 2019 | 17 | 0.730 |
Why?
| Receptors, Opioid, delta | 2 | 2018 | 25 | 0.720 |
Why?
| Ethanol | 2 | 2021 | 323 | 0.690 |
Why?
| Alcohol Drinking | 1 | 2021 | 259 | 0.690 |
Why?
| Adamantane | 4 | 2020 | 33 | 0.680 |
Why?
| Glutamic Acid | 2 | 2018 | 111 | 0.670 |
Why?
| Analgesics, Opioid | 5 | 2018 | 500 | 0.670 |
Why?
| Enzyme Inhibitors | 3 | 2019 | 446 | 0.670 |
Why?
| Dopamine Plasma Membrane Transport Proteins | 3 | 2023 | 46 | 0.660 |
Why?
| Drug Interactions | 5 | 2021 | 206 | 0.640 |
Why?
| Psychoses, Substance-Induced | 1 | 2018 | 8 | 0.640 |
Why?
| Morphine Derivatives | 1 | 2018 | 30 | 0.640 |
Why?
| Serotonin Antagonists | 6 | 2009 | 31 | 0.640 |
Why?
| Vaccination | 1 | 2020 | 298 | 0.630 |
Why?
| Fever | 2 | 2017 | 129 | 0.630 |
Why?
| Cyclohexylamines | 1 | 2017 | 5 | 0.620 |
Why?
| Cyclohexanones | 1 | 2017 | 7 | 0.620 |
Why?
| Phencyclidine | 1 | 2017 | 21 | 0.620 |
Why?
| Stereoisomerism | 9 | 2016 | 106 | 0.590 |
Why?
| Fluorobenzenes | 7 | 2014 | 21 | 0.580 |
Why?
| Cannabis | 1 | 2019 | 149 | 0.570 |
Why?
| Brain Chemistry | 2 | 2007 | 75 | 0.560 |
Why?
| Receptor, Serotonin, 5-HT2C | 3 | 2010 | 7 | 0.510 |
Why?
| Visceral Pain | 1 | 2014 | 2 | 0.500 |
Why?
| Morphine Dependence | 1 | 2014 | 11 | 0.500 |
Why?
| Appetite | 1 | 2014 | 19 | 0.490 |
Why?
| Aporphines | 3 | 2016 | 6 | 0.480 |
Why?
| Reinforcement Schedule | 4 | 2020 | 64 | 0.480 |
Why?
| Disease Models, Animal | 5 | 2023 | 1647 | 0.460 |
Why?
| Structure-Activity Relationship | 5 | 2023 | 423 | 0.450 |
Why?
| Substance Withdrawal Syndrome | 3 | 2019 | 179 | 0.450 |
Why?
| Fenclonine | 2 | 2017 | 6 | 0.430 |
Why?
| Physical Conditioning, Animal | 1 | 2012 | 59 | 0.420 |
Why?
| p-Chloroamphetamine | 1 | 2011 | 2 | 0.420 |
Why?
| Microsomes, Liver | 4 | 2020 | 214 | 0.400 |
Why?
| Humans | 28 | 2023 | 54391 | 0.400 |
Why?
| Brain | 8 | 2020 | 1392 | 0.390 |
Why?
| Receptor, Serotonin, 5-HT1A | 2 | 2007 | 4 | 0.380 |
Why?
| Pain | 2 | 2013 | 405 | 0.380 |
Why?
| Head | 1 | 2010 | 78 | 0.370 |
Why?
| Macaca mulatta | 7 | 2011 | 106 | 0.360 |
Why?
| Movement | 1 | 2010 | 111 | 0.360 |
Why?
| Narcotic Antagonists | 4 | 2018 | 126 | 0.340 |
Why?
| Ketanserin | 4 | 2014 | 9 | 0.310 |
Why?
| Random Allocation | 2 | 2020 | 312 | 0.290 |
Why?
| Crowding | 2 | 2004 | 16 | 0.290 |
Why?
| Microglia | 1 | 2007 | 137 | 0.280 |
Why?
| Chromatography, High Pressure Liquid | 4 | 2020 | 377 | 0.280 |
Why?
| Serotonin Receptor Agonists | 1 | 2005 | 14 | 0.270 |
Why?
| Diterpenes | 1 | 2005 | 32 | 0.270 |
Why?
| Receptors, Opioid, kappa | 1 | 2005 | 40 | 0.270 |
Why?
| Neurotoxicity Syndromes | 1 | 2006 | 52 | 0.270 |
Why?
| Psychotropic Drugs | 1 | 2005 | 82 | 0.260 |
Why?
| Tetrabenazine | 1 | 2004 | 12 | 0.250 |
Why?
| Opioid-Related Disorders | 2 | 2019 | 367 | 0.250 |
Why?
| Norepinephrine Plasma Membrane Transport Proteins | 1 | 2023 | 10 | 0.240 |
Why?
| Receptors, Cannabinoid | 2 | 2014 | 20 | 0.240 |
Why?
| Binding, Competitive | 4 | 2013 | 113 | 0.240 |
Why?
| Serotonin Plasma Membrane Transport Proteins | 1 | 2023 | 51 | 0.230 |
Why?
| Amphetamine-Related Disorders | 2 | 2020 | 125 | 0.230 |
Why?
| Lysergic Acid Diethylamide | 3 | 2007 | 7 | 0.230 |
Why?
| Serotonin 5-HT2 Receptor Antagonists | 2 | 2014 | 9 | 0.220 |
Why?
| Social Isolation | 1 | 2003 | 29 | 0.220 |
Why?
| Metabolic Networks and Pathways | 2 | 2020 | 104 | 0.220 |
Why?
| Pentylenetetrazole | 1 | 2022 | 9 | 0.220 |
Why?
| Diazepam | 1 | 2022 | 18 | 0.220 |
Why?
| Cytochrome P-450 CYP3A | 2 | 2020 | 82 | 0.220 |
Why?
| Analysis of Variance | 2 | 2017 | 634 | 0.210 |
Why?
| Tremor | 1 | 2022 | 18 | 0.210 |
Why?
| Fluoxetine | 2 | 2017 | 47 | 0.210 |
Why?
| Amides | 1 | 2022 | 43 | 0.210 |
Why?
| Benzodiazepines | 1 | 2022 | 70 | 0.210 |
Why?
| Carrier Proteins | 1 | 2023 | 360 | 0.210 |
Why?
| Rats, Long-Evans | 1 | 2021 | 29 | 0.200 |
Why?
| Alcohol Deterrents | 1 | 2021 | 9 | 0.200 |
Why?
| Housing, Animal | 1 | 2021 | 16 | 0.200 |
Why?
| Central Nervous System Depressants | 1 | 2021 | 78 | 0.200 |
Why?
| Artificial Gene Fusion | 1 | 2020 | 13 | 0.190 |
Why?
| Immunoglobulin Fc Fragments | 1 | 2020 | 12 | 0.190 |
Why?
| Spiro Compounds | 2 | 2010 | 8 | 0.180 |
Why?
| Electroencephalography | 1 | 2022 | 357 | 0.180 |
Why?
| Microsomes | 1 | 2020 | 45 | 0.180 |
Why?
| Adrenergic Uptake Inhibitors | 1 | 2019 | 17 | 0.180 |
Why?
| Rodentia | 1 | 2020 | 19 | 0.180 |
Why?
| Single-Chain Antibodies | 1 | 2020 | 28 | 0.180 |
Why?
| Psychopharmacology | 1 | 2019 | 5 | 0.180 |
Why?
| Reaction Time | 2 | 2018 | 227 | 0.180 |
Why?
| GTP-Binding Proteins | 2 | 2017 | 94 | 0.180 |
Why?
| Corpus Striatum | 1 | 2019 | 67 | 0.180 |
Why?
| Catalepsy | 1 | 2019 | 9 | 0.170 |
Why?
| Molecular Structure | 5 | 2014 | 319 | 0.170 |
Why?
| Genetic Therapy | 1 | 2020 | 121 | 0.170 |
Why?
| Nociception | 1 | 2019 | 13 | 0.170 |
Why?
| Morpholines | 2 | 2017 | 64 | 0.170 |
Why?
| Taste | 1 | 2018 | 37 | 0.160 |
Why?
| Cytochrome P-450 Enzyme System | 2 | 2017 | 192 | 0.160 |
Why?
| alpha-Methyltyrosine | 1 | 2017 | 5 | 0.160 |
Why?
| Phthalimides | 1 | 2017 | 3 | 0.160 |
Why?
| Propiophenones | 1 | 2017 | 4 | 0.160 |
Why?
| Time Factors | 2 | 2019 | 3210 | 0.150 |
Why?
| Fetus | 1 | 2019 | 228 | 0.150 |
Why?
| Prenatal Exposure Delayed Effects | 1 | 2019 | 172 | 0.150 |
Why?
| Animals, Newborn | 2 | 2019 | 396 | 0.150 |
Why?
| Buprenorphine | 1 | 2019 | 135 | 0.150 |
Why?
| Reproducibility of Results | 1 | 2021 | 1301 | 0.150 |
Why?
| Benzoxazines | 1 | 2017 | 18 | 0.150 |
Why?
| Data Interpretation, Statistical | 2 | 2007 | 177 | 0.150 |
Why?
| Mice, Inbred Strains | 3 | 2012 | 199 | 0.140 |
Why?
| Tandem Mass Spectrometry | 3 | 2014 | 248 | 0.140 |
Why?
| Serotonin 5-HT1 Receptor Agonists | 1 | 2016 | 6 | 0.140 |
Why?
| Positron-Emission Tomography | 2 | 2009 | 323 | 0.140 |
Why?
| Rats, Inbred F344 | 2 | 2007 | 209 | 0.140 |
Why?
| Oxidation-Reduction | 4 | 2020 | 383 | 0.140 |
Why?
| Blood-Brain Barrier | 1 | 2016 | 59 | 0.140 |
Why?
| Schizophrenia | 1 | 2018 | 267 | 0.140 |
Why?
| Recombinant Proteins | 4 | 2020 | 570 | 0.140 |
Why?
| Marijuana Abuse | 1 | 2018 | 149 | 0.140 |
Why?
| Receptors, Serotonin | 2 | 2007 | 22 | 0.130 |
Why?
| Cerebral Cortex | 2 | 2007 | 234 | 0.130 |
Why?
| Blood Pressure | 1 | 2018 | 587 | 0.130 |
Why?
| Psychomotor Performance | 2 | 2013 | 156 | 0.120 |
Why?
| Endothelial Cells | 1 | 2016 | 294 | 0.120 |
Why?
| Antipsychotic Agents | 1 | 2016 | 241 | 0.120 |
Why?
| Fentanyl | 1 | 2014 | 34 | 0.120 |
Why?
| Urinalysis | 1 | 2014 | 50 | 0.120 |
Why?
| Membranes | 1 | 2013 | 19 | 0.120 |
Why?
| Memory | 2 | 2011 | 124 | 0.110 |
Why?
| Drug Synergism | 1 | 2013 | 171 | 0.110 |
Why?
| Metabolomics | 1 | 2013 | 149 | 0.110 |
Why?
| Pain Measurement | 1 | 2013 | 248 | 0.110 |
Why?
| Adrenergic Agents | 1 | 2011 | 17 | 0.100 |
Why?
| Metabolic Detoxication, Phase I | 1 | 2011 | 11 | 0.100 |
Why?
| Kinetics | 3 | 2020 | 692 | 0.100 |
Why?
| Pyrazoles | 1 | 2012 | 110 | 0.100 |
Why?
| Oxalates | 1 | 2011 | 15 | 0.100 |
Why?
| Receptors, sigma | 1 | 2011 | 13 | 0.100 |
Why?
| Analgesics, Non-Narcotic | 1 | 2012 | 140 | 0.100 |
Why?
| Ethylamines | 1 | 2010 | 3 | 0.100 |
Why?
| Aminopyridines | 1 | 2010 | 16 | 0.100 |
Why?
| Linear Models | 1 | 2011 | 308 | 0.100 |
Why?
| Cricetulus | 3 | 2017 | 102 | 0.090 |
Why?
| CHO Cells | 3 | 2017 | 123 | 0.090 |
Why?
| Amphetamine | 1 | 2010 | 42 | 0.090 |
Why?
| Tissue Distribution | 2 | 2013 | 178 | 0.090 |
Why?
| Models, Animal | 2 | 2011 | 255 | 0.090 |
Why?
| Saimiri | 1 | 2009 | 2 | 0.090 |
Why?
| Nortropanes | 1 | 2009 | 2 | 0.090 |
Why?
| Tropanes | 1 | 2009 | 4 | 0.090 |
Why?
| Electrochemical Techniques | 1 | 2009 | 15 | 0.090 |
Why?
| Microdialysis | 1 | 2009 | 21 | 0.090 |
Why?
| Fluorine Radioisotopes | 1 | 2009 | 25 | 0.090 |
Why?
| Female | 7 | 2020 | 28471 | 0.090 |
Why?
| Receptors, Opioid | 1 | 2009 | 17 | 0.090 |
Why?
| Sulfonamides | 1 | 2010 | 146 | 0.090 |
Why?
| Cells, Cultured | 1 | 2013 | 1737 | 0.090 |
Why?
| Food | 1 | 2009 | 69 | 0.080 |
Why?
| Polymorphism, Genetic | 2 | 2020 | 193 | 0.080 |
Why?
| Magnetic Resonance Spectroscopy | 1 | 2009 | 255 | 0.080 |
Why?
| Neostriatum | 1 | 2007 | 13 | 0.080 |
Why?
| Isoquinolines | 1 | 2007 | 25 | 0.080 |
Why?
| Imidazoles | 1 | 2009 | 143 | 0.080 |
Why?
| Primates | 1 | 2007 | 20 | 0.080 |
Why?
| Ligands | 3 | 2013 | 229 | 0.080 |
Why?
| Piperazines | 1 | 2007 | 115 | 0.070 |
Why?
| Pyridines | 1 | 2007 | 137 | 0.070 |
Why?
| Cocaine-Related Disorders | 1 | 2009 | 246 | 0.070 |
Why?
| Generalization, Stimulus | 1 | 2005 | 2 | 0.070 |
Why?
| Benzeneacetamides | 1 | 2005 | 9 | 0.070 |
Why?
| Injections, Intravenous | 1 | 2006 | 148 | 0.070 |
Why?
| Diterpenes, Clerodane | 1 | 2005 | 20 | 0.070 |
Why?
| Premedication | 1 | 2005 | 18 | 0.070 |
Why?
| Racemases and Epimerases | 1 | 2005 | 15 | 0.070 |
Why?
| Injections, Intraperitoneal | 1 | 2005 | 59 | 0.070 |
Why?
| Naloxone | 1 | 2005 | 61 | 0.070 |
Why?
| Body Weight | 1 | 2007 | 578 | 0.060 |
Why?
| Reactive Oxygen Species | 2 | 2018 | 491 | 0.060 |
Why?
| Tritium | 1 | 2004 | 53 | 0.060 |
Why?
| Electrochemistry | 1 | 2004 | 29 | 0.060 |
Why?
| Radioligand Assay | 1 | 2004 | 49 | 0.060 |
Why?
| Cognition Disorders | 1 | 2006 | 240 | 0.060 |
Why?
| Tomography, Emission-Computed | 1 | 2004 | 53 | 0.060 |
Why?
| Protein Binding | 2 | 2020 | 736 | 0.060 |
Why?
| Prazosin | 1 | 2004 | 11 | 0.060 |
Why?
| Adrenergic alpha-Antagonists | 1 | 2004 | 24 | 0.060 |
Why?
| Biomedical Research | 1 | 2007 | 241 | 0.060 |
Why?
| Infusions, Intravenous | 1 | 2004 | 231 | 0.060 |
Why?
| Cognition | 1 | 2006 | 350 | 0.060 |
Why?
| ROC Curve | 1 | 2004 | 259 | 0.060 |
Why?
| Lethal Dose 50 | 1 | 2003 | 21 | 0.060 |
Why?
| Drug Inverse Agonism | 2 | 2013 | 18 | 0.060 |
Why?
| Cold Temperature | 1 | 2003 | 53 | 0.060 |
Why?
| Brain Mapping | 1 | 2004 | 250 | 0.060 |
Why?
| Cricetinae | 2 | 2013 | 209 | 0.050 |
Why?
| Chromatography, Liquid | 2 | 2014 | 243 | 0.050 |
Why?
| Hydroxylation | 2 | 2012 | 61 | 0.050 |
Why?
| Platelet Aggregation Inhibitors | 1 | 2003 | 179 | 0.050 |
Why?
| Cytochrome P-450 CYP2D6 | 1 | 2020 | 25 | 0.050 |
Why?
| Uridine Diphosphate Glucuronic Acid | 1 | 2019 | 10 | 0.040 |
Why?
| Dependovirus | 1 | 2020 | 102 | 0.040 |
Why?
| Attitude | 1 | 2019 | 81 | 0.040 |
Why?
| Mice, Inbred BALB C | 1 | 2020 | 370 | 0.040 |
Why?
| Malate Dehydrogenase | 1 | 2018 | 11 | 0.040 |
Why?
| Intestines | 1 | 2020 | 204 | 0.040 |
Why?
| Risk | 1 | 2019 | 343 | 0.040 |
Why?
| Vascular Stiffness | 1 | 2018 | 20 | 0.040 |
Why?
| Pharmacists | 1 | 2019 | 152 | 0.040 |
Why?
| Cyclohexanols | 1 | 2017 | 23 | 0.040 |
Why?
| PC12 Cells | 1 | 2017 | 31 | 0.040 |
Why?
| Glucuronosyltransferase | 1 | 2019 | 157 | 0.040 |
Why?
| Sex Factors | 1 | 2020 | 766 | 0.040 |
Why?
| Dopamine Agents | 1 | 2016 | 19 | 0.040 |
Why?
| Cell Death | 1 | 2017 | 223 | 0.040 |
Why?
| Receptors, Dopamine D4 | 1 | 2016 | 9 | 0.040 |
Why?
| Microvessels | 1 | 2016 | 34 | 0.040 |
Why?
| Glutathione | 1 | 2017 | 330 | 0.030 |
Why?
| Cattle | 1 | 2016 | 225 | 0.030 |
Why?
| Necrosis | 1 | 2016 | 208 | 0.030 |
Why?
| HEK293 Cells | 1 | 2016 | 245 | 0.030 |
Why?
| Mice, Inbred C57BL | 1 | 2020 | 2001 | 0.030 |
Why?
| Vesicular Monoamine Transport Proteins | 1 | 2014 | 49 | 0.030 |
Why?
| Cross-Sectional Studies | 1 | 2019 | 1696 | 0.030 |
Why?
| Paper | 1 | 2013 | 16 | 0.030 |
Why?
| Capsules | 1 | 2013 | 34 | 0.030 |
Why?
| Pentanones | 1 | 2013 | 9 | 0.030 |
Why?
| Nitric Oxide | 1 | 2016 | 298 | 0.030 |
Why?
| Methylamines | 1 | 2013 | 16 | 0.030 |
Why?
| Powders | 1 | 2013 | 32 | 0.030 |
Why?
| Solid Phase Extraction | 1 | 2013 | 12 | 0.030 |
Why?
| Tablets | 1 | 2013 | 31 | 0.030 |
Why?
| MicroRNAs | 1 | 2018 | 386 | 0.030 |
Why?
| Arkansas | 1 | 2019 | 2100 | 0.030 |
Why?
| Conditioning, Classical | 1 | 2013 | 34 | 0.030 |
Why?
| Liver | 1 | 2020 | 1226 | 0.030 |
Why?
| Mitochondria | 1 | 2017 | 490 | 0.030 |
Why?
| Drug Design | 1 | 2013 | 133 | 0.030 |
Why?
| Drug Partial Agonism | 1 | 2012 | 7 | 0.030 |
Why?
| Drug Antagonism | 1 | 2012 | 10 | 0.030 |
Why?
| Cell Proliferation | 1 | 2016 | 1097 | 0.030 |
Why?
| Pregnancy | 1 | 2019 | 2639 | 0.030 |
Why?
| Glucuronidase | 1 | 2011 | 48 | 0.020 |
Why?
| Cell Membrane | 1 | 2012 | 279 | 0.020 |
Why?
| Drug Evaluation, Preclinical | 1 | 2011 | 158 | 0.020 |
Why?
| Fluoroacetates | 1 | 2009 | 1 | 0.020 |
Why?
| Iodobenzenes | 1 | 2009 | 1 | 0.020 |
Why?
| Trifluoroacetic Acid | 1 | 2009 | 1 | 0.020 |
Why?
| Molecular Targeted Therapy | 1 | 2011 | 128 | 0.020 |
Why?
| Cyclization | 1 | 2009 | 6 | 0.020 |
Why?
| Adrenergic alpha-1 Receptor Antagonists | 1 | 2009 | 8 | 0.020 |
Why?
| Receptors, Adrenergic, alpha-1 | 1 | 2009 | 12 | 0.020 |
Why?
| Appetite Depressants | 1 | 2009 | 10 | 0.020 |
Why?
| Alfentanil | 1 | 2009 | 2 | 0.020 |
Why?
| Capsaicin | 1 | 2009 | 17 | 0.020 |
Why?
| Central Nervous System Agents | 1 | 2009 | 11 | 0.020 |
Why?
| Benzimidazoles | 1 | 2009 | 54 | 0.020 |
Why?
| Pruritus | 1 | 2009 | 52 | 0.020 |
Why?
| Hot Temperature | 1 | 2009 | 199 | 0.020 |
Why?
| Respiratory Insufficiency | 1 | 2009 | 127 | 0.020 |
Why?
| Problem Solving | 1 | 2006 | 46 | 0.020 |
Why?
| Attention | 1 | 2006 | 185 | 0.020 |
Why?
| Learning | 1 | 2006 | 171 | 0.020 |
Why?
|
|
Fantegrossi's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|